Interleukin-6 as A Prognostic Biomarker in Perinatal Asphyxia.
Developmental delay
Hypoxic Ischemic Encephalopathy
Interleukin-6 (IL-6)
Perinatal Asphyxia
Journal
Iranian journal of child neurology
ISSN: 1735-4668
Titre abrégé: Iran J Child Neurol
Pays: Iran
ID NLM: 101463836
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
06
2018
accepted:
27
05
2020
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
21
7
2021
Statut:
ppublish
Résumé
Early diagnosis is has a crucial role in both prevention and treatment of asphyxia-related complications. The current study aimed to evaluate the prognostic value of interleukin-6 (IL-6) and hypoxic-ischemic encephalopathy grade in the prediction of mortality and the developmental status of neonates affected by prenatal asphyxia. This cohort study was conducted on 38 term asphyxiated infants at Ghaem hospital, Mashhad, Iran, from 2013 to 2017. The HIE grade and serum IL-6 levels were determined at the time of birth. The developmental status was evaluated using the Denver II test at the end of the two-year follow-up. HIE grade 3 resulted in 83% mortality rate and developmental delay among all survivors. The mean IL-6 level was 2.7 ng/ml in the control group (not affected HIE), which increased up to 29, 175, and 136 ng/ml in those with HIE grades of 1, 2, and 3, respectively. According to the ROC curve analysis, the cut-off level of 24 pg/ml could predict the developmental delay with sensitivity and specificity of 96 and 92%, respectively. The IL-6 level and HIE grade are potential prognostic biomarkers for the determination of mortality and morbidity in asphyxiated neonates.
Identifiants
pubmed: 34282369
doi: 10.22037/ijcn.v15i3.21773
pmc: PMC8272543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119-130Déclaration de conflit d'intérêts
None declared.
Références
Hear Res. 2005 Sep;207(1-2):59-67
pubmed: 15913932
Pediatr Neurol. 2004 Nov;31(5):326-32
pubmed: 15519113
Indian Pediatr. 2009 Jan;46 Suppl:s67-70
pubmed: 19279374
Heliyon. 2020 Apr 26;6(4):e03793
pubmed: 32368646
J Trop Pediatr. 2009 Feb;55(1):8-14
pubmed: 18621775
EPMA J. 2011 Jun;2(2):197-210
pubmed: 23199149
Clin Med Insights Pediatr. 2017 Dec 10;11:1179556517746646
pubmed: 29276422
Interdiscip Toxicol. 2008 Dec;1(3-4):211-3
pubmed: 21218117
Pediatrics. 1997 Nov;100(5):789-94
pubmed: 9346977
Am J Obstet Gynecol. 2001 Mar;184(4):724-30
pubmed: 11262479
Arch Neurol. 1976 Oct;33(10):696-705
pubmed: 987769
J Pediatr. 1967 Aug;71(2):181-91
pubmed: 6029467
Eur J Clin Invest. 2003 Apr;33(4):352-8
pubmed: 12662167
Ment Retard Dev Disabil Res Rev. 2001;7(1):56-64
pubmed: 11241883
J Biol Chem. 1995 May 12;270(19):11463-71
pubmed: 7744784
Indian Pediatr. 2005 Sep;42(9):928-34
pubmed: 16208054
J Pediatr. 2003 Nov;143(5):625-9
pubmed: 14615734
Int J Gynaecol Obstet. 1999 Jun;65(3):267-72
pubmed: 10428347
Front Neurol. 2012 Nov 02;3:144
pubmed: 23130015
Biol Neonate. 2006;89(3):183-9
pubmed: 16244469